Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2

被引:39
作者
Zweemer, Annelien J. M. [1 ]
Bunnik, Julia [1 ]
Veenhuizen, Margo [1 ]
Miraglia, Fabiana [1 ]
Lenselink, Eelke B. [1 ]
Vilums, Maris [1 ]
de Vries, Henk [1 ]
Gibert, Arthur [1 ]
Thiele, Stefanie [2 ]
Rosenkilde, Mette M. [2 ]
IJzerman, Adriaan P. [1 ]
Heitman, Laura H. [1 ]
机构
[1] Leiden Univ, Leiden Acad Ctr Drug Res, Dept Med Chem, NL-2333 CC Leiden, Netherlands
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Neurosci & Pharmacol, Copenhagen, Denmark
关键词
PROTEIN-COUPLED RECEPTORS; SMALL-MOLECULE; PHARMACOLOGICAL CHARACTERIZATION; EXTRACELLULAR LOOP; DRUG DISCOVERY; ACTIVATION; IDENTIFICATION; COMPLEX; GPCR; ACETYLCHOLINE;
D O I
10.1124/mol.114.093328
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chemokine receptor CCR2 is a G protein-coupled receptor that is involved in many diseases characterized by chronic inflammation, and therefore a large variety of CCR2 small molecule antagonists has been developed. On the basis of their chemical structures these antagonists can roughly be divided into two groups with most likely two topographically distinct binding sites. The aim of the current study was to identify the binding site of one such group of ligands, exemplified by three allosteric antagonists, CCR2-RA-[R], JNJ-27141491, and SD-24. We first used a chimeric CCR2/CCR5 receptor approach to obtain insight into the binding site of the allosteric antagonists and additionally introduced eight single point mutations in CCR2 to further characterize the putative binding pocket. All constructs were studied in radioligand binding and/or functional IP turnover assays, providing evidence for an intracellular binding site for CCR2-RA-[R], JNJ-27141491, and SD-24. For CCR2-RA-[R] the most important residues for binding were found to be the highly conserved tyrosine Y-7.53 and phenylalanine F-8.50 of the NPxxYx((5,6))F motif, as well as V-6.36 at the bottom of TM-VI and K-8.49 in helix-VIII. These findings demonstrate for the first time the presence of an allosteric intracellular binding site for CCR2 antagonists. This contributes to an increased understanding of the interactions of diverse ligands at CCR2 and may allow for a more rational design of future allosteric antagonists.
引用
收藏
页码:358 / 368
页数:11
相关论文
共 49 条
  • [1] An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5
    Andrews, Glen
    Jones, Carolyn
    Wreggett, Keith A.
    [J]. MOLECULAR PHARMACOLOGY, 2008, 73 (03) : 855 - 867
  • [2] Ballesteros J. A., 1995, Neuroscience Methods, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471]
  • [3] Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
    Boring, L
    Gosling, J
    Cleary, M
    Charo, IF
    [J]. NATURE, 1998, 394 (6696) : 894 - 897
  • [4] Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344
    Brodmerkel, CM
    Huber, R
    Covington, M
    Diamond, S
    Hall, L
    Collins, R
    Leffet, L
    Gallagher, K
    Feldman, P
    Collier, P
    Stow, M
    Gu, XM
    Baribaud, F
    Shin, N
    Thomas, B
    Burn, T
    Hollis, G
    Yeleswaram, S
    Solomon, K
    Friedman, S
    Wang, AL
    Xue, CB
    Newton, RC
    Scherle, P
    Vaddi, K
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (08) : 5370 - 5378
  • [5] Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor
    de Kruijf, Petra
    van Heteren, Jane
    Lim, Herman D.
    Conti, Paolo G. M.
    van der Lee, Miranda M. C.
    Bosch, Leontien
    Ho, Koc-Kan
    Auld, Douglas
    Ohlmeyer, Michael
    Smit, Martin J.
    Wijkmans, Jac C. H. M.
    Zaman, Guido J. R.
    Smit, Martine J.
    Leurs, Rob
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 329 (02) : 783 - 790
  • [6] DELEAN A, 1980, J BIOL CHEM, V255, P7108
  • [7] Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1
    Dowal, Louisa
    Sim, Derek S.
    Dilks, James R.
    Blair, Price
    Beaudry, Sarah
    Denker, Bradley M.
    Koukos, Georgios
    Kuliopulos, Athan
    Flaumenhaft, Robert
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (07) : 2951 - 2956
  • [8] Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor
    Doyon, Julien
    Coesemans, Erwin
    Boeckx, Staf
    Buntinx, Mieke
    Hermans, Bart
    Van Wauwe, Jean P.
    Gilissen, Ron A. H. J.
    De Groot, Alex H. J.
    Corens, David
    Van Lommen, Guy
    [J]. CHEMMEDCHEM, 2008, 3 (04) : 660 - 669
  • [9] Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: Role of secreted MCP-1 in the regulation of the chemotactic response
    Fantuzzi, L
    Borghi, P
    Ciolli, V
    Pavlakis, G
    Belardelli, F
    Gessani, S
    [J]. BLOOD, 1999, 94 (03) : 875 - 883
  • [10] Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation
    Fritze, O
    Filipek, S
    Kuksa, V
    Palczewski, K
    Hofmann, KP
    Ernst, OP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) : 2290 - 2295